의료용 종양학 소프트웨어 시장 : 시장 규모, 점유율, 성장률, 산업 분석 - 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of medical oncology software Market

The global medical oncology software market is witnessing steady growth due to the rising burden of cancer worldwide and the increasing adoption of digital healthcare solutions. In 2025, the market size stood at USD 2.88 billion and is expected to grow to USD 3.08 billion in 2026. Over the long term, the market is projected to reach USD 6.18 billion by 2034, expanding at a CAGR of 9.10% during the forecast period. North America dominated the global market with a 41.00% share in 2025, driven by advanced healthcare infrastructure and high cancer prevalence.

Medical oncology software supports healthcare providers in managing systemic cancer treatments such as chemotherapy, immunotherapy, targeted therapy, and hormone therapy. These systems help streamline patient data management, treatment planning, clinical decision support, and monitoring of adverse effects, improving overall treatment accuracy and efficiency.

Market Drivers

One of the primary growth drivers is the increasing incidence of cancer globally. The growing patient pool has created a strong demand for efficient patient record management and treatment planning solutions. According to the American Cancer Society, nearly 1.96 million new cancer cases were projected in the U.S. in 2023, highlighting the rising pressure on oncology care systems.

Another major driver is the rapid adoption of electronic health records (EHRs) and healthcare digitization. Integration of medical oncology software with EHRs enables seamless access to patient history, lab reports, and imaging data, improving clinical decision-making and workflow efficiency. Additionally, rising investments in cancer research and informatics-based solutions are further accelerating market growth.

Market Trends

A key trend shaping the market is the development of personalized cancer treatment plans using genomic data. Medical oncology software increasingly incorporates advanced algorithms to analyze genetic mutations and biomarkers, enabling precision medicine. These tools assist oncologists in selecting targeted therapies and optimizing treatment regimens based on individual patient profiles.

The use of cloud-based oncology software is also expanding rapidly due to scalability, cost efficiency, and easier data integration. In 2026, the cloud segment accounted for 54.55% of the market share, supported by rising cloud infrastructure adoption and new product launches.

Challenges and Restraints

Despite strong growth potential, the market faces challenges related to cybersecurity risks and data breaches. Increasing cyberattacks on healthcare systems threaten patient data confidentiality and can disrupt cancer treatment workflows. For instance, ransomware attacks on oncology software providers have previously led to treatment delays and operational disruptions, negatively impacting patient trust and software adoption.

Segmentation Insights

By application, patient record management dominated the market with a 54.87% share, driven by the need for streamlined data coordination among healthcare providers. Treatment planning and clinical decision support segments are also growing steadily due to increasing demand for efficient and data-driven oncology care.

By end-user, hospitals and specialty clinics led the market with a 74.03% share, supported by widespread adoption of oncology software, established IT infrastructure, and the expansion of cancer care centers worldwide.

Regional Analysis

North America generated USD 1.18 billion in revenue in 2025, supported by high cancer prevalence and strong presence of leading market players. Europe followed with steady growth due to increasing research collaborations and digital infrastructure development. The Asia Pacific region is expected to grow at the fastest CAGR, driven by rising cancer cases, aging populations, and expanding digital oncology initiatives in countries such as China, Japan, and India.

Competitive Landscape

The market is highly consolidated, with key players such as Varian Medical Systems (Siemens Healthineers), Elekta, Epic Systems Corporation, Oracle (Cerner), and Philips holding significant shares. Strategic partnerships, acquisitions, and innovation-driven product launches continue to strengthen their global market presence.

Conclusion

The global medical oncology software market is set for sustained expansion, driven by rising cancer prevalence, increasing adoption of EHR-integrated solutions, and advancements in precision medicine. With the market growing from USD 2.88 billion in 2025 to USD 6.18 billion by 2034, medical oncology software is becoming a critical component of modern cancer care. Continued investments in cloud-based platforms, genomic integration, and data security will play a pivotal role in shaping the future of oncology informatics during the forecast period.

Segmentation By Deployment Type

• Clouds
• On-premise
• Hybrid

By Application

• Treatment Planning
• Patient Record Management
• Clinical Decision Support
• Others

By End User

• Hospitals & Specialty Clinics
• Diagnostic Centers
• Research Institutes
• Others

By Region

• North America (By Deployment Type, Application, End-user, and Country)
  • U.S.
  • Canada
• Europe (By Deployment Type, Application, End-user, and Country/sub-region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Deployment Type, Application, End-user, and Country/sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Deployment Type, Application, and End-user)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Deployment Type, Application, and End-user)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Cancer, by Key Countries, in 2023/2026
• 4.2. Recent Technological Advancements in Medical Oncology Software
• 4.3. New Product Launches by Market Players
• 4.4. Key Industry Developments - Mergers, Acquisitions, Partnerships
• 4.5. Impact of COVID-19 on the Market

5. Global Medical Oncology Software Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Deployment Type
  • 5.1.1. Clouds
  • 5.1.2. On-premise
  • 5.1.3. Hybrid
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Treatment Planning
  • 5.2.2. Patient Record Management
  • 5.2.3. Clinical Decision Support
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals & Specialty Clinics
  • 5.3.2. Diagnostic Centers
  • 5.3.3. Research Institutes
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Medical Oncology Software Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Deployment Type
  • 6.1.1. Clouds
  • 6.1.2. On-premise
  • 6.1.3. Hybrid
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Treatment Planning
  • 6.2.2. Patient Record Management
  • 6.2.3. Clinical Decision Support
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals & Specialty Clinics
  • 6.3.2. Diagnostic Centers
  • 6.3.3. Research Institutes
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Medical Oncology Software Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Deployment Type
  • 7.1.1. Clouds
  • 7.1.2. On-premise
  • 7.1.3. Hybrid
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Treatment Planning
  • 7.2.2. Patient Record Management
  • 7.2.3. Clinical Decision Support
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals & Specialty Clinics
  • 7.3.2. Diagnostic Centers
  • 7.3.3. Research Institutes
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. Germany
  • 7.4.2. U.K.
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Medical Oncology Software Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Deployment Type
  • 8.1.1. Clouds
  • 8.1.2. On-premise
  • 8.1.3. Hybrid
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Treatment Planning
  • 8.2.2. Patient Record Management
  • 8.2.3. Clinical Decision Support
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals & Specialty Clinics
  • 8.3.2. Diagnostic Centers
  • 8.3.3. Research Institutes
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Medical Oncology Software Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Deployment Type
  • 9.1.1. Clouds
  • 9.1.2. On-premise
  • 9.1.3. Hybrid
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Treatment Planning
  • 9.2.2. Patient Record Management
  • 9.2.3. Clinical Decision Support
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals & Specialty Clinics
  • 9.3.2. Diagnostic Centers
  • 9.3.3. Research Institutes
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Medical Oncology Software Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Deployment Type
  • 10.1.1. Clouds
  • 10.1.2. On-premise
  • 10.1.3. Hybrid
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Treatment Planning
  • 10.2.2. Patient Record Management
  • 10.2.3. Clinical Decision Support
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Hospitals & Specialty Clinics
  • 10.3.2. Diagnostic Centers
  • 10.3.3. Research Institutes
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2026)
• 11.2. Company Profiles
  • 11.2.1. Epic Systems Corporation
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Altai, Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Varian Medical Systems, Inc. (Siemens Healthineers AG)
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Cerner Corporation (Oracle)
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. American Medical Software
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Elekta
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. EndoSoft LLC
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. RaySearch Laboratories
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. MCKESSON CORPORATION
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Koninklijke Philips N.V.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)